← All trials
NCT04667078
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2021
- Primary completion
- Sep 15, 2023
- Completion date
- Sep 15, 2026
- First posted
- Dec 14, 2020
- Last posted
- Jun 25, 2021
- Enrollment
- 368
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Adolphe Rothschild Ophtalmologic FoundationLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.